A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

Recruiting

Phase 3

DexpramipexoleA Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

Sponsor:

Areteia Therapeutics

Code:

NCT05813288

Conditions

Eosinophilic Asthma

Asthma; Eosinophilic

Asthma

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Dexpramipexole Dihydrochloride

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-05. This information was provided to ClinicalTrials.gov by Areteia Therapeutics on 2025-08-14.